Cov khoom

S-(+)-Methyl-(2-chlorophenyl) [(2-(2-thienyl)amino] acetate hydrochloride, tseem hu ua S-(+)-Clopidogrel, yog ib qho chaw tshuaj nrog cov tshuaj formula C16H16ClNO2S · HCl Nws yog ib qho chiral derivative ntawm clopidogrel, uas yog ib qho tseem ceeb ntawm cov tshuaj antiplatelet.Qhov kev siv ntawm S-(+)-Methyl-(2-chlorophenyl) [(2-(2-thienyl)amino] acetate hydrochloride yog ib qho active. Cov khoom xyaw hauv kev tsim cov tshuaj plawv, tshwj xeeb yog cov tshuaj antiplatelet, nws siv nws cov teebmeem kho mob los ntawm inhibiting platelet aggregation, tiv thaiv kev tsim cov ntshav txhaws, thiab txo cov kev pheej hmoo ntawm cov kab mob plawv. Los ntawm irreversibly khi rau cov receptor no, S-(+)-Methyl-(2-chlorophenyl) [(2-(2-thienyl)amino] acetate hydrochloride inhibits platelet activation thiab tiv thaiv kev tsim. Hom kev ua no ua rau nws yog ib qho tshuaj tseem ceeb rau kev tiv thaiv cov kab mob thrombotic hauv cov neeg mob uas muaj kev pheej hmoo siab, xws li cov neeg uas muaj keeb kwm mob plawv, ischemic stroke, lossis peripheral artery disease.S-(+)-Methyl- (2-chlorophenyl)[(2-(2-thienyl)amino] acetate hydrochloride feem ntau yog siv rau qhov ncauj hauv daim ntawv ntsiav tshuaj lossis tshuaj ntsiav.Tom qab noj tshuaj, nws nkag mus rau hauv lub siab hloov pauv hauv lub siab los tsim nws cov metabolite nquag.Cov metabolite nquag no khi irreversibly rau P2Y12 receptor, exerting nws cov teebmeem antiplatelet rau lub sijhawm ntev.Cov tshuaj feem ntau yog muab tshuaj ib zaug ib hnub, xws li kev kho mob ib leeg lossis ua ke nrog lwm cov tshuaj tiv thaiv kab mob, xws li tshuaj aspirin.Nws yog ib qho tseem ceeb kom nco ntsoov tias S-(+)-Methyl-(2-chlorophenyl) [(2-(2 -thienyl)amino] acetate hydrochloride yuav tsum tsuas yog siv raws li kev taw qhia ntawm tus kws kho mob, vim tias nws siv yuav muaj peev xwm.